Tosedostat is a potent inhibitor of the M1 family of aminopeptidases, specifically targeting prolyl hydroxylase and LTA4 hydrolase, and has been investigated in clinical trials for conditions such as acute… Read more
Tosedostat is a potent inhibitor of the M1 family of aminopeptidases, specifically targeting prolyl hydroxylase and LTA4 hydrolase, and has been investigated in clinical trials for conditions such as acute myeloid leukemia, multiple myeloma, and pancreatic cancer. To support pharmaceutical development, the Tosedostat category includes a range of analytical tools such as reference standards for the active pharmaceutical ingredient (API), associated pharmacopeial and non-pharmacopeial impurities, and stable isotope labelled compounds. These high-quality materials are essential for accurate impurity profiling, method validation, and rigorous quality control testing. By providing standardized compounds for complex analytical procedures, these products assist researchers and analytical laboratories in ensuring the precision and reliability of their drug characterization and stability studies throughout the lifecycle of the compound.